ES2194861T3 - Peptidos opiodes. - Google Patents

Peptidos opiodes.

Info

Publication number
ES2194861T3
ES2194861T3 ES94901304T ES94901304T ES2194861T3 ES 2194861 T3 ES2194861 T3 ES 2194861T3 ES 94901304 T ES94901304 T ES 94901304T ES 94901304 T ES94901304 T ES 94901304T ES 2194861 T3 ES2194861 T3 ES 2194861T3
Authority
ES
Spain
Prior art keywords
amino acid
acid selected
image
identifying group
dimethoxyphenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901304T
Other languages
English (en)
Inventor
Sun Hyuk Kim
Jacques-Pierre Moreau
John E Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of ES2194861T3 publication Critical patent/ES2194861T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PEPTIDOS OPIODES QUE INCLUYEN LOS DE FORMULA (I), EN EL QUE A1 ES EL GRUPO IDENTIFICADOR DE UN ACIDO AMINO SELECCIONADO DE DIHIDROXIFENILALANINA-3,4, DIMETOXIFENILALANINA-3,4, AZATIROSINA, Y DIMETILTIROSINA-2,6; A2 ES EL GRUPO IDENTIFICADOR DE UN ACIDO AMINO SELECCIONADO DE D-ALA Y D-ARG; A3 ES H, O EL GRUPO IDENTIFICADOR DE UN ACIDO AMINO SELECCIONADO DE DIHIDROXIFENILALANINA-3,4 Y DIMETOXIFENILALANINA-3,4, A4 ES H, CICLOHEXILMETILO, EL GRUPO IDENTIFICADOR DE UN ACIDO AMINO SELECCIONADO DE DIHIDROXIFENILALANINA-3,4, DIMETOXIFENILALANINA-3,4, PHE, Y PHE SUSTITUIDO CON SU ANILLO BENCENO SUSTITUIDO POR HALOGENO, NO2, OH, O CH3; A5 ES EL GRUPO IDENTIFICADOR DE UN ACIDO AMINO-L O -D SELECCIONADO DE LEU, NLE, LYS, MET Y MET(O), O ES SUPRIMIDO JUNTO CON EL R4-CH LIGADO A ELLO; CADA R1 Y R2 SON -H, -C(NH2)=NH, O ALQUILO C1-12; R3 ES -(A) O (B); R4 ES (C);(D), O (E); Y R5 ES -(CH2)N+1OH, (F), O (G); EN DONDE M ES 0-6, N ES 0-6, Y X ES H, ALQUILO C1-12, ARILO C6-12, ARALQUILO C7-18, ALCARILO C7-18,PIRIDILALQUILO C6-17, O ALQUILPIRIDILO C6-17; PROVISTOS QUE CUANDO UNO DE R1 Y R2 SON C(NH2) = NH, EL OTRO DEBE SER H; O SUS SALES ACEPTABLES FARMACEUTICAMENTE.
ES94901304T 1992-11-12 1993-11-04 Peptidos opiodes. Expired - Lifetime ES2194861T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97494392A 1992-11-12 1992-11-12

Publications (1)

Publication Number Publication Date
ES2194861T3 true ES2194861T3 (es) 2003-12-01

Family

ID=25522535

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901304T Expired - Lifetime ES2194861T3 (es) 1992-11-12 1993-11-04 Peptidos opiodes.

Country Status (15)

Country Link
US (1) US5663295A (es)
EP (1) EP0644772B1 (es)
JP (1) JPH07503485A (es)
AT (1) ATE235911T1 (es)
AU (1) AU672077B2 (es)
CA (1) CA2126697A1 (es)
CZ (1) CZ168194A3 (es)
DE (1) DE69332826T2 (es)
DK (1) DK0644772T3 (es)
ES (1) ES2194861T3 (es)
NZ (1) NZ258345A (es)
PL (1) PL304662A1 (es)
PT (1) PT644772E (es)
RU (1) RU94035760A (es)
WO (1) WO1994011018A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1164141A3 (en) * 1994-02-21 2002-01-02 AstraZeneca AB Opioid peptides and their use for treatment of pain
SE9503924D0 (sv) * 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
WO1996032409A1 (en) * 1995-04-12 1996-10-17 Kyowa Hakko Kogyo Co., Ltd. Plant cell growth factor
KR19990044554A (ko) * 1995-09-11 1999-06-25 요이치로 다케다 펩티드 유도체
JP3746847B2 (ja) * 1996-08-02 2006-02-15 協和醗酵工業株式会社 植物細胞増殖因子
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
TW509699B (en) 1998-09-24 2002-11-11 Chugau Pharmaceutical Co Ltd Ethylamine derivatives
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
EP1275657A4 (en) 2000-04-14 2006-06-28 Nippon Shinyaku Co Ltd PEPTIDE DERIVATIVES AND MEDICINAL COMPOSITIONS
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
EP2475988B1 (en) 2009-09-09 2018-11-14 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
WO2011104649A1 (en) * 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
CA2817111C (en) 2010-11-10 2019-03-05 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3681900A4 (en) * 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP3710467A4 (en) 2017-11-17 2021-08-04 Cytogel Pharma, LLC MU-OPIOID RECEPTOR POLYMERIC AGONISTS
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN111635335B (zh) * 2020-06-24 2021-07-13 上海交通大学 一种手性γ-氨基酸的合成方法及采用该方法合成的手性γ-氨基酸
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291839A (en) * 1976-01-26 1977-08-02 Wellcome Found Peptide and derivatives
US4216128A (en) * 1979-07-05 1980-08-05 American Home Products Corporation Enkephalin analogues
US4599325A (en) * 1984-02-16 1986-07-08 G. D. Searle & Co. Substituted tyrosyl alanine dipeptide amides
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof

Also Published As

Publication number Publication date
CA2126697A1 (en) 1994-05-26
JPH07503485A (ja) 1995-04-13
CZ168194A3 (en) 1994-12-15
DE69332826D1 (de) 2003-05-08
PL304662A1 (en) 1995-01-09
PT644772E (pt) 2003-08-29
EP0644772B1 (en) 2003-04-02
NZ258345A (en) 1996-03-26
EP0644772A1 (en) 1995-03-29
WO1994011018A1 (en) 1994-05-26
DK0644772T3 (da) 2003-06-30
AU5594394A (en) 1994-06-08
US5663295A (en) 1997-09-02
ATE235911T1 (de) 2003-04-15
AU672077B2 (en) 1996-09-19
EP0644772A4 (en) 1997-01-29
DE69332826T2 (de) 2004-01-29
RU94035760A (ru) 1996-08-10

Similar Documents

Publication Publication Date Title
ES2194861T3 (es) Peptidos opiodes.
MX9304970A (es) ACIDOS ß-AMINOALQUIL- Y ß-N-PEPTIDILAMINOALQUIL-BORONICOS.
CY1111740T1 (el) Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων
ES2044841T3 (es) Procedimiento de preparacion de peptidos sinteticos con actividad de interleuquin 1 humana.
KR850004594A (ko) 펩타이드의 제조방법
CA2060034A1 (en) Tumour growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
DK0646127T3 (da) Polypeptidbombesinantagonister
EP1323730A4 (en) NEW POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THEM
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
PT1226160E (pt) Novos peptidos antiarritmicos
KR890701571A (ko) 4h-3, 1-벤즈옥사진-4-온 화합물 및 세린 프로테아제 억제를 위한 그의 약학 조성물
KR950005320A (ko) 위장 운동 자극 활성을 가지는 폴리펩티드
ATE125548T1 (de) Peptide.
GB992957A (en) New decapeptides and their manufacture
DK0745093T3 (da) Hidtil ukendte oligopeptoder med affinitet til opioidreceptorer
DK0737691T3 (da) Bombesinanaloger
ES2056046T3 (es) Dipeptidos y procedimiento.
JPS5225768A (en) Preparation of novel pentapeptides
ES416516A1 (es) Un procedimiento para la preparacion de nonapeptidos.
KR870007206A (ko) 폴리펩타이드 화합물